Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company

MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector

Fineline Cube Nov 1, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...

Company

Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024

Fineline Cube Nov 1, 2024

US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...

Company Deals

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer

Fineline Cube Nov 1, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Drug

CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume

Fineline Cube Nov 1, 2024

The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...

Company Drug

AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China

Fineline Cube Nov 1, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...

Company Drug

Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA

Fineline Cube Nov 1, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Company Drug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

Fineline Cube Nov 1, 2024

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...

Company Deals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Fineline Cube Nov 1, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...

Company Drug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Fineline Cube Nov 1, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...

Company Drug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Fineline Cube Nov 1, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...

Company Drug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

Fineline Cube Nov 1, 2024

China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins UK Approval for NSCLC Treatment

Fineline Cube Oct 31, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has received marketing approval from the UK Medicines and Healthcare...

Company

Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales

Fineline Cube Oct 31, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...

Company

Amgen Reports Q3 2024 Revenues of USD 8.5 Billion, Marking a 23% YOY Increase

Fineline Cube Oct 31, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced its financial results for the third quarter...

Company Deals

HOB Biotech Group and Sino Biopharmaceutical Ltd Form Strategic Partnership in Allergy Treatments

Fineline Cube Oct 31, 2024

Jiangsu-based HOB Biotech Group Corp., Ltd (SHA: 688656) has announced a strategic cooperation agreement with...

Company

Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY

Fineline Cube Oct 31, 2024

Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...

Company

Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses

Fineline Cube Oct 31, 2024

Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...

Company Deals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Fineline Cube Oct 31, 2024

China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...

Posts pagination

1 … 293 294 295 … 684

Recent updates

  • NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)
  • China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally
  • China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework
  • Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders
  • Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Policy / Regulatory

China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally

Policy / Regulatory

China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.